Ilyang Pharmaceutical Co.,Ltd (007570.KS)
KRW 10880.0
(-2.07%)
KRW 10880.0
(-2.07%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 205.87 Billion KRW | -0.22% |
| 2022 | 206.33 Billion KRW | -7.27% |
| 2021 | 222.51 Billion KRW | 14.58% |
| 2020 | 194.19 Billion KRW | -9.56% |
| 2019 | 214.71 Billion KRW | -3.44% |
| 2018 | 222.37 Billion KRW | -1.34% |
| 2017 | 225.39 Billion KRW | 5.37% |
| 2016 | 213.9 Billion KRW | -3.04% |
| 2015 | 220.62 Billion KRW | -10.81% |
| 2014 | 247.36 Billion KRW | 15.32% |
| 2013 | 214.5 Billion KRW | 9.56% |
| 2012 | 195.78 Billion KRW | 6.82% |
| 2011 | 183.28 Billion KRW | -3.73% |
| 2010 | 190.38 Billion KRW | 18.49% |
| 2009 | 160.67 Billion KRW | 8.68% |
| 2008 | 147.84 Billion KRW | 53.52% |
| 2007 | 96.3 Billion KRW | 14.33% |
| 2006 | 84.23 Billion KRW | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q2 | 235.59 Billion KRW | 8.8% |
| 2024 Q1 | 216.53 Billion KRW | 5.18% |
| 2023 FY | 205.87 Billion KRW | -0.22% |
| 2023 Q4 | 205.87 Billion KRW | -5.42% |
| 2023 Q3 | 217.67 Billion KRW | 11.18% |
| 2023 Q2 | 195.78 Billion KRW | 2.74% |
| 2023 Q1 | 190.55 Billion KRW | -7.64% |
| 2022 Q4 | 206.33 Billion KRW | -2.03% |
| 2022 Q3 | 210.61 Billion KRW | 4.49% |
| 2022 FY | 206.33 Billion KRW | -7.27% |
| 2022 Q1 | 198.75 Billion KRW | -10.68% |
| 2022 Q2 | 201.56 Billion KRW | 1.41% |
| 2021 Q4 | 222.51 Billion KRW | 3.21% |
| 2021 Q1 | 210.49 Billion KRW | 8.39% |
| 2021 Q2 | 199.13 Billion KRW | -5.4% |
| 2021 Q3 | 215.58 Billion KRW | 8.26% |
| 2021 FY | 222.51 Billion KRW | 14.58% |
| 2020 Q4 | 194.19 Billion KRW | -13.8% |
| 2020 Q1 | 212.88 Billion KRW | -0.85% |
| 2020 Q3 | 225.27 Billion KRW | 4.55% |
| 2020 FY | 194.19 Billion KRW | -9.56% |
| 2020 Q2 | 215.48 Billion KRW | 1.22% |
| 2019 Q2 | 221.66 Billion KRW | -1.08% |
| 2019 FY | 214.71 Billion KRW | -3.44% |
| 2019 Q4 | 214.71 Billion KRW | -2.44% |
| 2019 Q3 | 220.07 Billion KRW | -0.71% |
| 2019 Q1 | 224.08 Billion KRW | 0.77% |
| 2018 Q3 | 231.66 Billion KRW | 5.16% |
| 2018 Q4 | 222.37 Billion KRW | -4.01% |
| 2018 FY | 222.37 Billion KRW | -1.34% |
| 2018 Q1 | 227.82 Billion KRW | 1.08% |
| 2018 Q2 | 220.3 Billion KRW | -3.3% |
| 2017 FY | 225.39 Billion KRW | 5.37% |
| 2017 Q3 | 231.28 Billion KRW | 4.26% |
| 2017 Q2 | 221.84 Billion KRW | 0.68% |
| 2017 Q1 | 220.34 Billion KRW | 3.01% |
| 2017 Q4 | 225.39 Billion KRW | -2.55% |
| 2016 Q1 | 223.32 Billion KRW | 0.0% |
| 2016 Q3 | 229.4 Billion KRW | 2.06% |
| 2016 Q2 | 224.77 Billion KRW | 0.65% |
| 2016 FY | 213.9 Billion KRW | -3.04% |
| 2016 Q4 | 213.9 Billion KRW | -6.75% |
| 2015 FY | 220.62 Billion KRW | -10.81% |
| 2015 Q3 | 233.19 Billion KRW | 2.81% |
| 2015 Q2 | 226.8 Billion KRW | -8.31% |
| 2015 Q1 | 247.36 Billion KRW | 0.62% |
| 2014 FY | 247.36 Billion KRW | 15.32% |
| 2014 Q2 | 236.74 Billion KRW | 10.37% |
| 2014 Q4 | 245.84 Billion KRW | -5.01% |
| 2014 Q3 | 258.81 Billion KRW | 9.32% |
| 2014 Q1 | 214.5 Billion KRW | 0.0% |
| 2013 FY | 214.5 Billion KRW | 9.56% |
| 2013 Q1 | 195.78 Billion KRW | 1.85% |
| 2012 Q4 | 192.22 Billion KRW | 0.26% |
| 2012 Q3 | 191.72 Billion KRW | 3.65% |
| 2012 Q1 | 183.28 Billion KRW | -2.17% |
| 2012 FY | 195.78 Billion KRW | 6.82% |
| 2012 Q2 | 184.98 Billion KRW | 0.92% |
| 2011 Q2 | 168.28 Billion KRW | -11.6% |
| 2011 FY | 183.28 Billion KRW | -3.73% |
| 2011 Q1 | 190.38 Billion KRW | 7.02% |
| 2011 Q3 | 183.58 Billion KRW | 9.09% |
| 2011 Q4 | 187.34 Billion KRW | 2.05% |
| 2010 Q3 | 163.49 Billion KRW | -2.46% |
| 2010 Q4 | 177.89 Billion KRW | 8.81% |
| 2010 Q2 | 167.61 Billion KRW | 0.0% |
| 2010 FY | 190.38 Billion KRW | 18.49% |
| 2009 Q1 | 147.84 Billion KRW | 13.31% |
| 2009 FY | 160.67 Billion KRW | 8.68% |
| 2009 Q4 | 165.24 Billion KRW | 20.92% |
| 2009 Q3 | 136.66 Billion KRW | -6.24% |
| 2009 Q2 | 145.75 Billion KRW | -1.41% |
| 2008 Q2 | 116.51 Billion KRW | 20.99% |
| 2008 Q1 | 96.3 Billion KRW | 14.42% |
| 2008 Q4 | 130.48 Billion KRW | -14.88% |
| 2008 Q3 | 153.29 Billion KRW | 31.57% |
| 2008 FY | 147.84 Billion KRW | 53.52% |
| 2007 Q3 | 87.89 Billion KRW | -15.59% |
| 2007 FY | 96.3 Billion KRW | 14.33% |
| 2007 Q4 | 84.16 Billion KRW | -4.24% |
| 2007 Q2 | 104.12 Billion KRW | 0.0% |
| 2006 FY | 84.23 Billion KRW | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Yuyu Pharma, Inc. | 77.85 Billion KRW | -164.425% |
| Dong-A Socio Holdings Co., Ltd. | 929.79 Billion KRW | 77.858% |
| Ildong Holdings Co., Ltd. | 707.09 Billion KRW | 70.884% |
| HANDOK Inc. | 449.7 Billion KRW | 54.22% |
| Kukje Pharma Co., Ltd. | 85.67 Billion KRW | -140.311% |
| Yuhan Corporation | 712.33 Billion KRW | 71.099% |
| Dong-A ST Co., Ltd. | 631.91 Billion KRW | 67.42% |
| SAMSUNG PHARM. Co., LTD. | 15.89 Billion KRW | -1195.263% |
| Hanmi Pharm. Co., Ltd. | 851.82 Billion KRW | 75.831% |
| Hanall Biopharma Co.,Ltd | 53.52 Billion KRW | -284.608% |
| Dong Sung Bio Pharm.Co.,Ltd. | 75.17 Billion KRW | -173.876% |
| MYUNGMOON Pharm co.,Ltd | 147.79 Billion KRW | -39.299% |
| Hana Pharm Co., Ltd. | 70.4 Billion KRW | -192.431% |
| Yuyu Pharma, Inc. | 77.85 Billion KRW | -164.425% |
| Ilsung Pharmaceuticals Co., Ltd. | 36.43 Billion KRW | -465.029% |
| REYON Pharmaceutical Co., Ltd. | 251.15 Billion KRW | 18.027% |
| Aprogen pharmaceuticals,Inc. | 220.7 Billion KRW | 6.719% |
| JW Holdings Corporation | 827.51 Billion KRW | 75.121% |
| Ildong Pharmaceutical Co., Ltd. | 436.99 Billion KRW | 52.888% |
| Chong Kun Dang Pharmaceutical Corp. | 586.79 Billion KRW | 64.915% |
| JW Pharmaceutical Corporation | 379.59 Billion KRW | 45.765% |
| Shin Poong Pharm.Co.,Ltd. | 79.3 Billion KRW | -159.611% |
| Hyundai Pharmaceutical Co., Ltd. | 69.96 Billion KRW | -194.244% |
| Samil Pharmaceutical Co.,Ltd | 242.85 Billion KRW | 15.226% |
| Jeil Pharmaceutical Co.,Ltd | 330.29 Billion KRW | 37.669% |
| Yuyu Pharma, Inc. | 77.85 Billion KRW | -164.425% |
| Kwang Dong Pharmaceutical Co., Ltd. | 490.01 Billion KRW | 57.986% |
| Daewoong pharmaceutical Co.,Ltd | 858.02 Billion KRW | 76.006% |
| JW Pharmaceutical Corporation | 379.59 Billion KRW | 45.765% |
| Yuhan Corporation | 712.33 Billion KRW | 71.099% |
| Jeil Pharma Holdings Inc | 477.81 Billion KRW | 56.913% |
| Yungjin Pharm. Co., Ltd. | 136.96 Billion KRW | -50.309% |
| Suheung Co., Ltd. | 516.66 Billion KRW | 60.153% |
| JW Pharmaceutical Corporation | 379.59 Billion KRW | 45.765% |
| Samjin Pharmaceuticals Co., Ltd. | 154.53 Billion KRW | -33.221% |
| Korea United Pharm Inc. | 89.96 Billion KRW | -128.839% |
| CKD Bio Corp. | 170.76 Billion KRW | -20.564% |
| Daewon Pharmaceutical Co., Ltd. | 243.73 Billion KRW | 15.533% |
| Dongwha Pharm.Co.,Ltd | 157.65 Billion KRW | -30.584% |
| Whan In Pharm Co.,Ltd. | 43.01 Billion KRW | -378.567% |
| Shin Poong Pharm.Co.,Ltd. | 79.3 Billion KRW | -159.611% |
| Chong Kun Dang Holdings Corp. | 632.51 Billion KRW | 67.452% |
| Boryung Corporation | 373.1 Billion KRW | 44.822% |
| Bukwang Pharmaceutical Co., Ltd. | 208.19 Billion KRW | 1.115% |
| Ilyang Pharmaceutical Co.,Ltd | 205.87 Billion KRW | 0.0% |
| JW Lifescience Corporation | 96.44 Billion KRW | -113.468% |